

TEVA PHARMACEUTICAL INDUSTRIES LTD  
Form 6-K  
July 27, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**  
**PURSUANT TO RULE 13a-16 OR 15d-16**  
**UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of July, 2015**

**Commission File Number: 001-16174**

**Teva Pharmaceutical Industries Ltd.**  
**(Translation of registrant's name into English)**

**Israel**  
**(Jurisdiction of incorporation or organization)**

**5 Basel Street**

**P.O. Box 3190**

**Petach Tikva**

**4951033 Israel**

**(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: July 27, 2015

TEVA PHARMACEUTICAL INDUSTRIES  
LTD.,

By: /s/ Eyal Desheh  
Name: Eyal Desheh  
Title: Group EVP & CFO

**EXHIBIT INDEX**

| Exhibit<br>No. | Description   |
|----------------|---|
| 99.1           | Teva to Acquire Allergan Generics for \$40.5 Billion Creating a Transformative Generics and Specialty Company Well Positioned to Win in Global Healthcare |
| 99.2           | Teva Withdraws Proposal to Acquire Mylan  |
| 99.3           | Teva Reports Preliminary Second Quarter 2015 Results  |